Solving for Solubility.

A molecule cannot achieve its full potential if it cannot be effectively formulated or delivered.

One Process. Many Molecules.

Quicksol is not an animal-health technology. Ivermectin's husbandry history is what makes it a demanding demonstration molecule; the platform addresses poor aqueous solubility, a formulation challenge across pharmaceutical development.

Already published.
Soluvec, a concentrated aqueous ivermectin formulation created using the patented Quicksol process, has been evaluated in peer reviewed pharmacokinetic research published in Therapeutic Delivery.

The Science Doesn't End With One Application.

Each application inherits the same solubilization science; each advances on its own evidence and regulatory path.

Soluvec™

Soluvec, a concentrated aqueous ivermectin formulation created using the patented Quicksol process, has been evaluated in peer reviewed pharmacokinetic research published in Therapeutic Delivery.

Results reflect the published animal PK study and its oral comparator.

Patented oncology applications

The intellectual property portfolio includes a granted patent titled “Novel Injectable, Infusable, Instillable Ivermectin Adjuvant for Cancer Therapies”, with historical preclinical research across triple-negative breast cancer, metastatic melanoma and Lewis Lung Carcinoma models, and subsequent human cell-line tumor research.

These programs remain preclinical and do not represent an approved cancer therapy.

Preclinical antiviral research

A third party Biosafety Level 4 laboratory program evaluated the Company's solubilized ivermectin technology against three SARS-CoV-2 variants, demonstrating in vitro antiviral activity at the tested concentration after both 24 and 48 hours across all three variants, with additional animal research evaluating viral clearance.

This work was preclinical and did not establish Soluvec as an approved treatment for COVID-19.

Emerging applications

By changing the formulation characteristics of difficult molecules, Quicksol creates a platform for investigating new routes of administration, pharmacokinetic profiles and therapeutic applications.

Soluvec™Published Science. Measurable Performance.

Soluvec™ is an aqueous formulation of ivermectin developed using the Company's patented Quicksol solubilization technology. The formulation has undergone extensive development and has been evaluated in a peer reviewed pharmacokinetic study.

The published research demonstrated significant changes in the solubility and pharmacokinetic profile of ivermectin, including substantially increased aqueous solubility and systemic exposure relative to the oral comparator used in the study.

This work provides important independent scientific validation of the underlying Quicksol platform.

~2,500x

Aqueous solubility

Relative to free ivermectin.

~7x

Total systemic exposure

Parenteral Soluvec compared with the same dose as an oral ivermectin tablet in the published animal PK study.

48 hrs

Detectable systemic exposure

Ivermectin remained detectable at 48 hours in all Soluvec treated animals, compared with none of the orally dosed animals.

Results reflect the published animal PK study and its oral comparator.

View Peer Reviewed Publication

Why This MattersPoor aqueous solubility is not unique to ivermectin.

It is a common formulation challenge across pharmaceutical development.

The significance of Soluvec™ therefore extends beyond a single molecule or historical husbandry application. It provides a published demonstration of the Company's ability to materially alter the formulation characteristics of a poorly water soluble active pharmaceutical ingredient.

Explore the Evidence